The proceeds are intended to support 1nhaler's advance towards a regulatory filing for its DPI in 2027.

GINA 2026 no longer endorses a SABA alone for asthma, yet albuterol labels still list only bronchospasm. Airsupra adds exacerbation risk reduction for adults.

Add Yahoo as a preferred source to see more of our stories on Google. A new study shows that a dual-action inhaler cuts asthma attacks in children almost in half. (CREDIT: Imperial College London) For ...

The new research, published in ERJ Open Research, found that nearly one in five asthma patients and one in three COPD ...

The go-to asthma inhaler prescribed by pediatricians for decades has been discontinued, and patients and families are paying a steep price. Discontinued Inhaler Devastates Families On Jan. 10, Laura ...

Winter has arrived in most parts of the country, and the mercury has begun to drop. While this season is pleasant for many, ...

A device costing just pennies, based on an idea by a University of Manchester Professor to help his son use an inhaler, could be a gamechanger for asthma patients. The impressive results are from a ...

Add Yahoo as a preferred source to see more of our stories on Google. Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the ...

More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a new study says. In 2024, GlaxoSmithKline withdrew Flovent from the market.

In the first randomized controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be ...

SAN DIEGO — Asthma afflicts 8.1% of school-age children in the United States and is a leading cause of missed school and work. Having stock inhalers available at schools prevents asthma-related ...

Even if you don't have major asthma attacks, you may still be bothered by coughing or shortness of breath.For you, there is still room to review your treatment and aim for a state where symptoms are ...